Efficacy and safety of high-dose dexamethasone-based regimens in the newly diagnosed multiple myeloma patients with renal impairment.
- Author:
Jian LI
1
;
Dao-Bin ZHOU
;
Li JIAO
;
Ming-Hui DUAN
;
Wei ZHANG
;
Yong-Qiang ZHAO
;
Ti SHEN
Author Information
- Publication Type:Journal Article
- MeSH: Aged; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Dexamethasone; administration & dosage; Female; Humans; Male; Middle Aged; Multiple Myeloma; complications; drug therapy; Prognosis; Renal Insufficiency; complications; Retrospective Studies; Treatment Outcome
- From: Acta Academiae Medicinae Sinicae 2009;31(5):567-569
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of high-dose dexamethasone-based regiments in newly diagnosed multiple myeloma patients with renal impairment.
METHODSThe clinical data of 22 patients with newly diagnosed multiple myeloma patients with renal impairment who received high-dose dexamethasone-based regiments from August 2006 to August 2008 in Peking Union Medical College Hospital were retrospectively reviewed.
RESULTSAfter receiving a median 4 cycles of high-dose dexamethasone-based regiments, renal impairment was reversed in 7 patients (31.8%) with a median time to reversal of 31 days. Sixteen patients (72.7%) achieved overall response, including 7 patients (31.8%) had complete remission / near complete remission. The grade 3 or 4 adverse events included neutropenia (13.6%), infections (22.7%), peripheral neuropathy (9.1%), and ileus (4.5%).
CONCLUSIONThe high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment.
